Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Allosteric modulation of G protein-coupled receptors (GPCRs) represents a novel approach to the development of probes and therapeutics that is expected to enable subtype-specific regulation of central nervous system target receptors. The metabotropic glutamate receptors (mGlus) are class C GPCRs that play important neuromodulatory roles throughout the brain, as such they are attractive targets for therapeutic intervention for a number of psychiatric and neurological disorders including anxiety, depression, Fragile X Syndrome, Parkinson’s disease and schizophrenia. Over the last fifteen years, selective allosteric modulators have been identified for many members of the mGlu family. The vast majority of these allosteric modulators are thought to bind within the transmembrane-spanning domains of the receptors to enhance or inhibit functional responses. A combination of mutagenesis-based studies and pharmacological approaches are beginning to provide a better understanding of mGlu allosteric sites. Collectively, when mapped onto a homology model of the different mGlu subtypes based on the β2-adrenergic receptor, the previous mutagenesis studies suggest commonalities in the location of allosteric sites across different members of the mGlu family. In addition, there is evidence for multiple allosteric binding pockets within the transmembrane region that can interact to modulate one another. In the absence of a class C GPCR crystal structure, this approach has shown promise with respect to the interpretation of mutagenesis data and understanding structure-activity relationships of allosteric modulator pharmacophores.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637 · cited 2×
“To identify the sites at which allosteric modulators bind mGlus, initial mutational sites were chosen based on models predicting a pocket that may resemble the site where 11-cis-retinal, an inverse agonist, binds in bovine rhodopsin (Palczewski et al., 2000; Teller et al., 2001).”
BackgroundInfluentialCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · cited 1×
“Thus, allosteric modulation represents an exciting novel means of targeting GPCRs particularly for CNS disorders, a therapeutic area with one of the highest rates of attrition in drug discovery (Kola and Landis, 2004).”
BackgroundAltered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349 · cited 1×
“Indeed, psychostimulant adverse effects were reported in early fenobam clinical trials (Itil et al., 1978; Friedmann et al., 1980; Pecknold et al., 1982), although whether or not this was due to interactions with mGlu 5 , an unknown interaction or through the formation of active metabolites remains…”
BackgroundAllosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063 · cited 3×
“In brain regions implicated in the pathology of schizophrenia it is hypothesized that hypofunction of NMDA receptors leads to decreased downstream activation of GABAergic neurons resulting in disinhibition and an overall increase in excitation (Swanson et al., 2005; Conn et al., 2009a).”
BackgroundPatil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040 · cited 1×
“In a recent clinical trial, LY2140023, an oral prodrug of the orthosteric agonist LY404039, improved the positive and negative symptoms of schizophrenic patients with a similar efficacy to olanzapine, without the side effects associated with typical and atypical antipsychotics (Patil et al., 2007).”
BackgroundCorrection of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979 · cited 1×
“Administration of MPEP to FXS mice reduces anxiety and seizures (Yan et al., 2005), whilst crossbreeding of FXS mice with mGlu 5 knock-out mice suggest that a number of fragile X phenotypes can be corrected by reducing levels of mGlu 5 (Dolen et al., 2007).”
BackgroundGasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., et al. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00082-9 · Cited by 725 · cited 1×
“…5 activity in electrophysiological preparations (O'Brien et al., 2003, 2004; Chen et al., 2007; Ayala et al., 2009) as well as in rodent behavioral models (Kinney et al., 2005; Balschun et al., 2006; Lecourtier et al., 2007; Gass and Olive, 2009; Uslaner et al., 2009; Stefani and Moghaddam, 2010).”
BackgroundA new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716 · cited 1×
“For example benzodiazepines, positive allosteric modulators (PAMs) of GABAA receptors, are an effective and safe treatment for anxiety and sleep disorders (Mohler et al., 2002).”
BackgroundFMR1 and the fragile X syndrome: Human genome epidemiology review
Crawford, D. C., Acuña, J. M., & Sherman, S. L. (2001) · Genetics in Medicine · doi:10.1097/00125817-200109000-00006 · Cited by 711 · cited 1×
“Fragile X Syndrome (FXS) is the leading cause of autism and the most common form of inherited mental retardation (Crawford et al., 2001; Garber et al., 2008).”
BackgroundEvolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors
Pin, J.-P., Galvez, T., & Prézeau, L. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00038-x · Cited by 662 · cited 2×
“Most class C GPCRs are distinguished by their large extracellular N-terminal domain, termed the Venus Flytrap domain (VFD), that contains the endogenous ligand-binding site (Pin et al., 2003).”
BackgroundMetabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP
Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521 · cited 2×
“Administration of MPEP to FXS mice reduces anxiety and seizures (Yan et al., 2005), whilst crossbreeding of FXS mice with mGlu 5 knock-out mice suggest that a number of fragile X phenotypes can be corrected by reducing levels of mGlu 5 (Dolen et al., 2007).”
BackgroundA pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 3×
“However, no psychostimulant effects or cognitive impairments were reported for fenobam in a recent trial in FXS patients, nor for another mGlu5 NAM, ADX10059 (Berry-Kravis et al., 2009; Keywood et al., 2009; Zerbib et al., 2010).”
BackgroundPorter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089839 · Cited by 308 · cited 3×
“Recently, fenobam, a non-benzodiazepine anxiolytic, was found to be a selective mGlu5 NAM (Porter et al., 2005).”
BackgroundKrystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1982-8 · Cited by 272
Johnson, M. P., Barda, D., Britton, T. C., Emkey, R., Hornback, W. J., Jagdmann, G. E., McKinzie, D. L., Nisenbaum, E. S., Tizzano, J. P., & Schoepp, D. D. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2099-9 · Cited by 156
Mechanisms of synaptic depression triggered by metabotropic glutamate receptors
Bellone, C., Lüscher, C., & Mameli, M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8263-3 · Cited by 150 · cited 1×
“Detailed discussion of the physiological roles of mGlus has been presented in multiple reviews (Coutinho and Knopfel, 2002; Conn and Pin, 1997; Anwyl, 1999; Valenti et al., 2002; Bellone et al., 2008; Pinheiro and Mulle, 2008).”
BackgroundBook Review: Metabotropic Glutamate Receptors: Electrical and Chemical Signaling Properties
Coutinho, V., & Knöpfel, T. (2002) · The Neuroscientist · doi:10.1177/1073858402238514 · Cited by 144 · cited 2×
“This modulation can range from robust excitation to more subtle changes in the pattern and frequency of cell firing and responses to excitatory inputs (Coutinho and Knopfel, 2002; Anwyl, 1999; Valenti et al., 2002).”
BackgroundFragile X: translation in action
Bear, M. F., Dölen, G., Osterweil, E., & Nagarajan, N. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301610 · Cited by 94 · cited 9×
“However, no psychostimulant effects or cognitive impairments were reported for fenobam in a recent trial in FXS patients, nor for another mGlu 5 NAM, ADX10059 (Berry-Kravis et al., 2009; Keywood et al., 2009; Zerbib et al., 2010).”
BackgroundInfluentialSynapse structure: glutamate receptors connected by the shanks
Ehlers, M. D. (1999) · Current Biology · doi:10.1016/s0960-9822(00)80043-3 · Cited by 93
Cited by
Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function
Won, H., Lee, H.-R., Gee, H. Y., Mah, W., Kim, J.-I., Lee, J., Ha, S., Chung, C., Jung, E. S., Cho, Y. S., et al. (2012) · Nature · doi:10.1038/nature11208 · Cited by 695
Action of Molecular Switches in GPCRs - Theoretical and Experimental Studies
Trzaskowski, B., Latek, D., Yuan, S., Ghoshdastider, U., Debinski, A., & Filipek, S. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799320556 · Cited by 469
Conn, P. J., Lindsley, C. W., Meiler, J., & Niswender, C. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4308 · Cited by 260
Self-citationNovel Allosteric Modulators of G Protein-coupled Receptors
Gentry, P. R., Sexton, P. M., & Christopoulos, A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.662759 · Cited by 199
“However, several ligands have been identified that are non-competitive with the MPEP site, including the PAMs VU357121 and CPPHA, indicating the presence of at least two distinct allosteric sites (67, 69, 73, 74).”
BackgroundInfluentialSpurrier, J., Nicholson, L., Fang, X. T., Stoner, A. J., Toyonaga, T., Holden, D., Siegert, T. R., Laird, W., Allnutt, M. A., Chiasseu, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi8593 · Cited by 114
Metadata
- Authors
- Gregory, K. J., Dong, E. N., Meiler, J., & Conn, P. J.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 60
- Issue
- 1
- Pages
- 66-81
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W1994864252
- Cited by
- 119
- References
- 20
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.